Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
The commenters requested that CMS apply this adjustment only to APC 5464
AOD-9604 was developed by Australian biotech company Metabolic Pharmaceuticals in the late 1990s as an attempt to isolate the fat-metabolizing properties of growth hormone without its growth-promoting effects
It selectively stimulates lipolysis through the beta-3 adrenergic receptor pathway without binding the growth hormone receptor or stimulating IGF-1
This sequential/parallel action provides rationale for combination use in research settings
So, injections are a more direct way to make sure your body gets the B12 it needs, while tablets might not work as efficiently because they have to go through your stomach and intestines first
For Canadians managing chronic conditions over many months, this difference translates to significant savings
